ANX005: Clinical Trials

2 trials of ANX005, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 recruiting. 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 32Completed 1, Recruiting 1

Follow ANX005: new trials by email Literature Review of ANX005 trials Research Report on ANX005

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
Tanruprubart - Guillain-Barre Syndrome
Phase 3RecruitingAnnexon, Inc.302025-09-122026-10-26
Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome
ANX005, Placebo - Guillain-Barre Syndrome
Phase 3CompletedAnnexon, Inc.2422020-12-172025-05-29

Conditions studied

Guillain-Barre Syndrome (2)

Sponsors

Annexon, Inc. (2)

Countries

Bangladesh (1)  ·  Denmark (1)  ·  France (1)  ·  Philippines (1)  ·  Spain (1)  ·  United Kingdom (1)  ·  United States (1)

NIH funding

2025 (1)